Luye Pharma Group Ltd. (LYPHF)

PNK: LYPHF · Real-Time Price · USD

0.27

0.01 (5.80%)

At close: Apr 29, 2025, 9:30 AM

Luye Pharma Income Statement

Financials in CNY. Fiscal year is January - December.

Fiscal Year	Q2 2024	Q4 2023	Q2 2023	Q4 2022	Q2 2022	Q4 2021	Q2 2021	Q4 2020	Q2 2020	Q4 2019	Q2 2019	Q4 2018	Q2 2018	Q4 2017	Q2 2017	Q4 2016	Q2 2016
Period Ending	Jun 30, 2024	Dec 31, 2023	Jun 30, 2023	Dec 31, 2022	Jun 30, 2022	Dec 31, 2021	Jun 30, 2021	Dec 31, 2020	Jun 30, 2020	Dec 31, 2019	Jun 30, 2019	Dec 31, 2018	Jun 30, 2018	Dec 31, 2017	Jun 30, 2017	Dec 31, 2016	Jun 30, 2016
Revenue	6.31B	6.14B	6.03B	5.98B	5.1B	5.2B	5.53B	5.54B	6.19B	6.36B	6.1B	5.17B	4.17B	3.81B	3.28B	2.92B	2.65B
Cost of Revenue	1.97B	1.94B	2B	1.84B	1.61B	1.8B	1.78B	1.55B	1.54B	1.48B	1.38B	1.12B	874.36M	851.48M	729.36M	535.05M	443.39M
Gross Profit	4.34B	4.2B	4.03B	4.14B	3.49B	3.4B	3.75B	3.99B	4.64B	4.88B	4.73B	4.05B	3.29B	2.96B	2.55B	2.38B	2.21B
Operating Income	1.34B	889.37M	549.25M	789.14M	288.45M	363.4M	761.74M	988.38M	1.52B	1.59B	1.63B	1.43B	1.14B	951.27M	770.46M	796.88M	802.75M
Interest Income	209.94M	465.49M	387.11M	295.65M	258.22M	209.77M	236.86M	272.95M	240.79M	150.66M	134.93M	78.97M	29.35M	48.1M	47.23M	54.65M	79.67M
Pretax Income	1B	700.1M	523.38M	669.76M	-187.62M	-74.56M	746.03M	942.17M	1.46B	1.63B	1.66B	1.47B	1.33B	1.12B	945.01M	974.72M	931.91M
Net Income	770.46M	532.61M	457.79M	604.81M	-223.98M	-134.39M	553.75M	706.59M	1.2B	1.4B	1.47B	1.3B	1.16B	981.37M	852.35M	891.54M	793.65M
Selling & General & Admin	2.43B	2.7B	2.71B	2.4B	2.33B	2.28B	2.12B	2.19B	2.42B	2.56B	2.45B	2.13B	1.79B	1.72B	1.54B	1.39B	1.23B
Research & Development	571.91M	586.16M	726.14M	857.34M	805.76M	683.16M	767.47M	789.87M	709.46M	711.13M	620.8M	491.16M	361.2M	288.7M	235.34M	193.66M	168.38M
Other Expenses	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Operating Expenses	3B	3.04B	3.12B	3.18B	3.42B	3.26B	2.76B	2.78B	2.95B	3.09B	2.93B	2.51B	1.99B	1.9B	1.65B	1.46B	1.35B
Interest Expense	n/a	694.04M	1.27B	578.19M	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Selling & Marketing Expenses	1.79B	2.06B	2.1B	1.82B	1.77B	1.7B	1.56B	1.66B	1.9B	2.03B	1.96B	1.69B	1.36B	1.29B	1.17B	1.12B	1.01B
Cost & Expenses	4.97B	4.98B	5.12B	5.02B	5.03B	5.07B	4.55B	4.32B	4.49B	4.57B	4.3B	3.63B	2.87B	2.75B	2.38B	2B	1.8B
Income Tax Expense	169.19M	161.02M	97.91M	86.47M	82.41M	90.67M	175.11M	238.91M	256.01M	279.83M	224.67M	167.47M	173.31M	135.76M	86.25M	80.73M	138.18M
Shares Outstanding (Basic)	3.76B	3.76B	3.69B	3.48B	3.48B	3.48B	3.42B	3.19B	3.2B	3.22B	3.22B	3.22B	3.22B	3.24B	3.28B	3.32B	3.32B
Shares Outstanding (Diluted)	3.76B	3.76B	3.69B	3.48B	3.48B	3.48B	3.43B	3.19B	3.2B	3.22B	3.22B	3.22B	3.22B	3.24B	3.28B	3.32B	3.32B
EPS (Basic)	0.20	0.14	0.13	0.17	-0.06	-0.04	0.17	0.22	0.37	0.42	0.44	0.39	0.36	0.30	0.26	0.27	0.24
EPS (Diluted)	0.20	0.14	0.13	0.17	-0.06	-0.04	0.17	0.22	0.37	0.42	0.44	0.39	0.36	0.30	0.26	0.27	0.24
EBITDA	1.97B	1.55B	1.19B	1.43B	887.47M	906.88M	1.26B	1.47B	1.99B	2.02B	2B	1.73B	1.44B	1.19B	933.44M	930.88M	918.31M
EBIT	1.28B	887.31M	549.12M	789.14M	288.45M	363.4M	761.74M	988.38M	1.52B	1.59B	1.63B	1.43B	1.14B	951.27M	770.46M	796.88M	802.75M
Depreciation & Amortization	683.22M	665.47M	641.29M	636.47M	599.02M	543.48M	494.44M	478.79M	464.21M	428.04M	363.36M	307.19M	299.8M	240.66M	162.98M	134.01M	115.56M